SCHEMBL24569481

SCHEMBL24569481

Cc1cc(N)ccc1Oc1ccc2c(c1)nnn2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 1/20 0.40
RAB9A P51151 5/20 0.39
NPC1 O15118 4/20 0.39
KDM4E B2RXH2 4/20 0.38
MAPT P10636 4/20 0.38
HSD17B10 Q99714 2/20 0.38
HTT P42858 1/20 0.38
KEAP1 Q14145 2/20 0.37
SLC9A1 P19634 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 3/20 0.35
POLB P06746 1/20 0.35
AHR P35869 1/20 0.35
GLA P06280 1/20 0.34
KLKB1 P03952 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29888093 0.91 KDM4E (0.35) HCAR3RAB9ANPC1KDM4EMAPT
SCHEMBL24569522 0.86 HCAR3 (0.39) HCAR3RAB9ANPC1KDM4EMAPT
SCHEMBL31475827 0.84 NPC1 (0.38) HCAR3RAB9ANPC1KDM4EMAPT
SCHEMBL31475900 0.84 HCAR3 (0.43) HCAR3RAB9ANPC1KDM4EMAPT
SCHEMBL31257464 0.84 KDM4E (0.43) HCAR3RAB9ANPC1KDM4EMAPT
SCHEMBL24569545 0.83 HCAR3 (0.45) HCAR3RAB9ANPC1KDM4EMAPT
SCHEMBL31476037 0.83 HCAR3 (0.36) HCAR3RAB9ANPC1KDM4EMAPT
SCHEMBL31475934 0.83 L3MBTL1 (0.34) HCAR3RAB9ANPC1KDM4EMAPT
SCHEMBL31475876 0.83 L3MBTL1 (0.34) HCAR3NPC1KDM4EMAPTL3MBTL1
SCHEMBL31476195 0.82 BRD4 (0.33) NPC1KDM4EMAPTKEAP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695256-A2 ERBB2 INHIBITORS Cogent Biosciences, Inc. (US) 2026-02-18 EP disclosed
US-20250129078-A1 ERBB2 INHIBITORS COGENT BIOSCIENCES, INC. 2025-04-24 US disclosed
WO-2024215809-A2 ERBB2 INHIBITORS COGENT BIOSCIENCES, INC. (US) 2024-10-17 WO disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129078-A1 ERBB2 INHIBITORS ERBB2, ERBB3, EGFR HCAR3 1765/4885RAB9A 1849/4885NPC1 2944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.